Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?

類似資料

• Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer
  著者:: KITAGAWA, CHIYOE, 等
  出版事項: (2019)
• Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
  著者:: Stinchcombe, Thomas E., 等
  出版事項: (2019)
• Response to Erlotinib in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component
  著者:: Paik, Paul K., 等
  出版事項: (2012)
• Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer
  著者:: Tay, Rebecca Yin, 等
  出版事項: (2018)
• Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
  著者:: Fukuhara, Tatsuro, 等
  出版事項: (2020)